Jim Simons
TARA icon

Jim Simons’s Protara Therapeutics TARA Stock Holding History

Jim Simons’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$655K Sell
125,700
-141,107
-53% -$835K ﹤0.01% 2484
2025
Q4 		$1.42M Sell
266,807
-47,493
-15% -$264K ﹤0.01% 2074
2025
Q3 		$1.37M Buy
314,300
+165,100
+111% +$535K ﹤0.01% 2320
2025
Q2 		$452K Buy
149,200
+19,800
+15% +$68.3K ﹤0.01% 2884
2025
Q1 		$551K Sell
129,400
-12,900
-9% -$57.6K ﹤0.01% 2702
2024
Q4 		$751K Sell
142,300
-194,440
-58% -$628K ﹤0.01% 2639
2024
Q3 		$616K Buy
336,740
+186,340
+124% +$383K ﹤0.01% 2688
2024
Q2 		$313K Buy
150,400
+65,800
+78% +$192K ﹤0.01% 2894
2024
Q1 		$339K Sell
84,600
-28,700
-25% -$92.6K ﹤0.01% 3038
2023
Q4 		$212K Buy
113,300
+53,200
+89% +$78.4K ﹤0.01% 3114
2023
Q3 		$100K Sell
60,100
-23,500
-28% -$53.8K ﹤0.01% 3247
2023
Q2 		$200K Buy
83,600
+24,694
+42% +$73.4K ﹤0.01% 3305
2023
Q1 		$184K Sell
58,906
-8,094
-12% -$26.7K ﹤0.01% 3305
2022
Q4 		$180K Sell
67,000
-12,200
-15% -$38.5K ﹤0.01% 3454
2022
Q3 		$234K Buy
79,200
+25,000
+46% +$84.7K ﹤0.01% 3319
2022
Q2 		$159K Buy
54,200
+16,600
+44% +$60.7K ﹤0.01% 3732
2022
Q1 		$192K Sell
37,600
-27,200
-42% -$143K ﹤0.01% 3662
2021
Q4 		$437K Sell
64,800
-51,100
-44% -$352K ﹤0.01% 3140
2021
Q3 		$802K Buy
115,900
+64,473
+125% +$503K ﹤0.01% 2669
2021
Q2 		$501K Buy
51,427
+20,027
+64% +$227K ﹤0.01% 2964
2021
Q1 		$494K Buy
31,400
+14,290
+84% +$265K ﹤0.01% 2909
2020
Q4 		$414K Sell
17,110
-20,676
-55% -$446K ﹤0.01% 2904
2020
Q3 		$636K Buy
37,786
+7,800
+26% +$181K ﹤0.01% 2735
2020
Q2 		$879K Buy
29,986
+4,100
+16% +$127K ﹤0.01% 2605
2020
Q1 		$595K Buy
25,886
+4,783
+23% +$139K ﹤0.01% 2672
2019
Q4 		$346K Buy
21,103
+1,917
+10% +$22K ﹤0.01% 3032
2019
Q3 		$200K Buy
19,186
+1,613
+9% +$23.1K ﹤0.01% 3148
2019
Q2 		$292K Buy
17,573
+6,179
+54% +$109K ﹤0.01% 3181
2019
Q1 		$229K Buy
11,394
+3,429
+43% +$391K ﹤0.01% 3171
2018
Q4 		$723K Sell
7,965
-445
-5% -$31.4K ﹤0.01% 2719
2018
Q3 		$656K Buy
8,410
+748
+10% +$69K ﹤0.01% 2765
2018
Q2 		$751K Buy
7,662
+1,759
+30% +$164K ﹤0.01% 2700
2018
Q1 		$590K Buy
5,903
+865
+17% +$78.7K ﹤0.01% 2856
2017
Q4 		$383K Buy
5,038
+740
+17% +$59.3K ﹤0.01% 2950
2017
Q3 		$344K Buy
4,298
+1,193
+38% +$68.3K ﹤0.01% 2875
2017
Q2 		$189K Buy
3,105
+1,792
+136% +$100K ﹤0.01% 3004
2017
Q1 		$92K Buy
1,313
+550
+72% +$41.1K ﹤0.01% 3090
2016
Q4 		$58K Buy
+763
New +$241K ﹤0.01% 3155

Other funds holding TARA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Jim Simons's TARA Position: Q1 2026 in Review

Jim Simons reduced its Protara Therapeutics (TARA) stake by 53% in Q1 2026, selling an estimated $835K and leaving 125,700 shares worth $655K. The position accounts for ﹤0.01% of the portfolio, ranked #2484.

Jim Simons first reported a position in TARA in Q4 2016 and has held it in 38 quarters since. The position peaked at $1.42M in Q4 2025. 114 funds tracked by Wall St. Rank hold TARA as of Q1 2026.

  • Jim Simons held 125,700 shares of Protara Therapeutics worth $655K as of Q1 2026.
  • Jim Simons sold 141,107 Protara Therapeutics shares in Q1 2026, an estimated $835K.
  • Protara Therapeutics made up ﹤0.01% of Jim Simons's portfolio in Q1 2026, its #2484 holding.
  • Jim Simons first reported a position in Protara Therapeutics in Q4 2016 and has held it in 38 quarters since.
  • Jim Simons's Protara Therapeutics position peaked at $1.42M in Q4 2025.
  • 114 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.